Compare Stocks: QNCX, IMDX, HURA, and INO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HURA TuHURA Biosciences	$2.14	$2.21	$0.41 ▼ $3.43	$136.38M	-0.02	280,617 shs	367,762 shs
IMDX Oncocyte	$4.13	$4.66	$2.40 ▼ $8.51	$135.15M	1.8	214,756 shs	183,522 shs
INO Inovio Pharmaceuticals	$1.43	$1.09	$0.56 ▼ $2.98	$147.86M	1.63	4.95 million shs	2.89 million shs
QNCX Quince Therapeutics	$31.32	$25.37	$15.10 ▼ $909.98	$31.85M	1.31	24,659 shs	37,860 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HURA TuHURA Biosciences	0.00%	+0.47%	+0.47%	+5.94%	-16.08%
IMDX Oncocyte	0.00%	+5.36%	-14.49%	-29.40%	+412,999,900.00%
INO Inovio Pharmaceuticals	0.00%	+12.60%	+114.07%	+30.00%	-48.75%
QNCX Quince Therapeutics	0.00%	-3.84%	+3.71%	+61.44%	-90.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HURA TuHURA Biosciences	$2.14	$2.21	$0.41 ▼ $3.43	$136.38M	-0.02	280,617 shs	367,762 shs
IMDX Oncocyte	$4.13	$4.66	$2.40 ▼ $8.51	$135.15M	1.8	214,756 shs	183,522 shs
INO Inovio Pharmaceuticals	$1.43	$1.09	$0.56 ▼ $2.98	$147.86M	1.63	4.95 million shs	2.89 million shs
QNCX Quince Therapeutics	$31.32	$25.37	$15.10 ▼ $909.98	$31.85M	1.31	24,659 shs	37,860 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HURA TuHURA Biosciences	0.00%	+0.47%	+0.47%	+5.94%	-16.08%
IMDX Oncocyte	0.00%	+5.36%	-14.49%	-29.40%	+412,999,900.00%
INO Inovio Pharmaceuticals	0.00%	+12.60%	+114.07%	+30.00%	-48.75%
QNCX Quince Therapeutics	0.00%	-3.84%	+3.71%	+61.44%	-90.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HURA TuHURA Biosciences	2.67	Moderate Buy	$9.00	320.56% Upside
IMDX Oncocyte	2.33	Hold	$10.50	154.24% Upside
INO Inovio Pharmaceuticals	2.75	Moderate Buy	$3.17	121.45% Upside
QNCX Quince Therapeutics	2.42	Hold	$260.00	730.14% Upside

Current Analyst Ratings Breakdown

Latest QNCX, IMDX, HURA, and INO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/26/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/20/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$68.00
8/18/2026	HURA TuHURA Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$9.00
8/18/2026	IMDX Oncocyte	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$9.00
8/18/2026	QNCX Quince Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$70.00
8/13/2026	INO Inovio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/13/2026	INO Inovio Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/13/2026	INO Inovio Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Positive	$1.80 ➝ $3.00
8/12/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	INO Inovio Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	$0.34 per share	N/A
IMDX Oncocyte	$4.05M	33.37	N/A	N/A	($1.10) per share	-3.75
INO Inovio Pharmaceuticals	$60K	2,464.37	N/A	N/A	$0.36 per share	3.97
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HURA TuHURA Biosciences	-$30.05M	-$0.54	N/A	N/A	N/A	N/A	-156.47%	-106.98%	11/13/2026 (Estimated)
IMDX Oncocyte	-$50.22M	-$1.49	N/A	N/A	N/A	-2,955.63%	N/A	-107.52%	N/A
INO Inovio Pharmaceuticals	-$84.95M	-$0.91	N/A	N/A	N/A	N/A	-669.94%	-73.97%	11/10/2026 (Estimated)
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-133.84%	11/11/2026 (Estimated)

Latest QNCX, IMDX, HURA, and INO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	HURA TuHURA Biosciences	-$0.1533	-$0.14	+$0.0133	-$0.14	N/A	N/A
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A
8/12/2026	Q2 2026	INO Inovio Pharmaceuticals	-$0.2167	-$0.07	+$0.1467	-$0.07	$0.53 million	N/A
8/10/2026	Q2 2026	IMDX Oncocyte	N/A	-$0.23	N/A	-$0.31	N/A	$0.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
HURA TuHURA Biosciences	N/A	N/A	N/A	N/A	N/A
IMDX Oncocyte	N/A	N/A	N/A	N/A	N/A
INO Inovio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HURA TuHURA Biosciences	0.20	0.18	0.18
IMDX Oncocyte	N/A	2.00	1.98
INO Inovio Pharmaceuticals	N/A	1.00	1.00
QNCX Quince Therapeutics	N/A	14.52	14.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HURA TuHURA Biosciences	0.62%
IMDX Oncocyte	55.35%
INO Inovio Pharmaceuticals	26.79%
QNCX Quince Therapeutics	30.75%

Insider Ownership

Company	Insider Ownership
HURA TuHURA Biosciences	6.06%
IMDX Oncocyte	2.21%
INO Inovio Pharmaceuticals	1.70%
QNCX Quince Therapeutics	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HURA TuHURA Biosciences	N/A	63.73 million	59.87 million	N/A
IMDX Oncocyte	120	32.72 million	32.00 million	N/A
INO Inovio Pharmaceuticals	320	103.40 million	101.64 million	Optionable
QNCX Quince Therapeutics	60	1.02 million	960,000	Optionable

QNCX, IMDX, HURA, and INO Headlines

Recent News About These Companies

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026 | quiverquant.comQ

Quince Therapeutics to Participate in September 2026 Investor Conferences

September 3, 2026 | globenewswire.com

Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $260.00 Average Price Target from Analysts

August 30, 2026 | americanbankingnews.com

Quince Therapeutics (NASDAQ:QNCX) Upgraded at Craig Hallum

August 30, 2026 | americanbankingnews.com

Quince Therapeutics Announces Planned Presidential Leadership Transition

August 27, 2026 | tipranks.com

Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

August 14, 2026 | globenewswire.com

Quince Therapeutics

July 6, 2026 | fool.com

Quince Therapeutics Stock Short Interest Report | NASDAQ:QNCX | Benzinga

July 2, 2026 | benzinga.com

Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

June 30, 2026 | globenewswire.com

Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

June 11, 2026 | seekingalpha.com

Quince Therapeutics Inc. (QNCX) Presents Positive Phase 2a Data for LAM-001 Inhaled Therapy

June 2, 2026 | insidermonkey.com

Quince Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk

May 24, 2026 | theglobeandmail.com

Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript

May 18, 2026 | seekingalpha.com

UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

May 18, 2026 | globenewswire.com

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

May 18, 2026 | globenewswire.com

Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60

May 15, 2026 | msn.com

Quince Therapeutics (QNCX) price target increased by 900.00% to 40.80

April 28, 2026 | msn.com

Quince Therapeutics Delays Annual 10-K Filing

April 27, 2026 | theglobeandmail.com

Quince Therapeutics settles $16.4M debt with $5.5M payment

March 30, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, IMDX, HURA, and INO Company Descriptions

TuHURA Biosciences NASDAQ:HURA

$2.14 0.00 (0.00%)

Closing price 09/4/2026 04:00 PM Eastern

Extended Trading

$2.12 -0.02 (-0.70%)

As of 08:38 AM Eastern

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Oncocyte NASDAQ:IMDX

$4.13 0.00 (0.00%)

Closing price 09/4/2026 04:00 PM Eastern

Extended Trading

$4.16 +0.03 (+0.70%)

As of 07:00 AM Eastern

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Inovio Pharmaceuticals NASDAQ:INO

$1.43 0.00 (0.00%)

Closing price 09/4/2026 04:00 PM Eastern

Extended Trading

$1.42 -0.01 (-0.42%)

As of 09:01 AM Eastern

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Quince Therapeutics NASDAQ:QNCX

$31.32 0.00 (0.00%)

Closing price 09/4/2026 04:00 PM Eastern

Extended Trading

$27.52 -3.80 (-12.12%)

As of 08:57 AM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, IMDX, HURA, and INO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, IMDX, HURA, and INO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, IMDX, HURA, and INO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, IMDX, HURA, and INO Company Descriptions

TuHURA Biosciences NASDAQ:HURA

Oncocyte NASDAQ:IMDX

Inovio Pharmaceuticals NASDAQ:INO

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest QNCX, IMDX, HURA, and INO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest QNCX, IMDX, HURA, and INO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

QNCX, IMDX, HURA, and INO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX, IMDX, HURA, and INO Company Descriptions

TuHURA Biosciences NASDAQ:HURA

Oncocyte NASDAQ:IMDX

Inovio Pharmaceuticals NASDAQ:INO

Quince Therapeutics NASDAQ:QNCX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools